Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat

By Dr. Matthew Watson

- Company receives FDA Priority Review with PDUFA date set for July 20, 2021 -

Original post:
Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat

Related Post


categoriaGlobal News Feed commentoComments Off on Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat | dataJanuary 25th, 2021

About...

This author published 3712 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research